Can Ozempic Help Treat Addiction? What a Groundbreaking New Study Means for Recovery
A landmark study published March 4, 2026 in The BMJ analyzing over 600,000 patients found that GLP-1 drugs like Ozempic and Mounjaro may reduce addiction risk by up to 25% and cut drug-related deaths by 50% among people already struggling with substance use disorders. Here’s what the science says, what it means for recovery, and what it doesn’t mean.
The Bottom Line
The research is promising but preliminary. GLP-1 drugs are NOT FDA-approved for addiction treatment. Clinical trials are underway and results are expected within months. But if you or a loved one is struggling with addiction right now, highly effective, proven treatments are available today — and every day matters.
What Are GLP-1 Drugs?
GLP-1 receptor agonists (glucagon-like peptide-1 drugs) are medications originally developed to treat type 2 diabetes. They work by mimicking a natural hormone that regulates blood sugar, slows digestion, and reduces appetite. Brand names include Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), and others.
These drugs have become some of the most widely prescribed medications in the United States, used by millions for diabetes and weight management. What researchers didn’t initially expect was the effect they appear to have on the brain’s reward system — the same circuitry that drives addiction.
According to Dr. Mary Shen at Brigham and Women’s Hospital, physicians began noticing something unexpected: patients on GLP-1 medications were spontaneously reporting that they had lost interest in alcohol, cigarettes, and other substances — without even trying to quit.[2]
From Anecdote to Evidence
Stories started appearing on social media and in clinical settings: people on Ozempic saying they simply stopped caring about alcohol, that the desire had “gone silent.” These observations prompted case reports, then preclinical studies, then larger analyses — and now this landmark BMJ study of over 600,000 patients.
What the Study Found
The study, led by Dr. Ziyad Al-Aly of Washington University School of Medicine and the VA St. Louis Health Care System, analyzed electronic health records from more than 600,000 U.S. Veterans Affairs patients with type 2 diabetes over three years. Researchers compared those who received GLP-1 drugs with those treated with SGLT2 inhibitors — a different diabetes medication class with no known effect on addiction.[1]
Reduced Risk of Developing New Addictions
Addiction Risk Reduction in GLP-1 Users
Source: Al-Aly et al., The BMJ, March 4, 2026
This translates to approximately 7 prevented cases of substance use disorder for every 1,000 GLP-1 users over three years. The protective effects appeared within the first year and persisted through the third year of observation.[1]
Reduced Harm Among People Already Struggling
Among patients already diagnosed with a substance use disorder, the results were even more dramatic:
Harm Reduction in People with Existing Addictions
Source: Al-Aly et al., The BMJ, March 4, 2026
That 50% reduction in drug-related deaths is particularly striking. In a country where over 79,000 people died from drug overdoses in 2024, and in North Carolina where overdose deaths have devastated communities across every county, a reduction of that magnitude would represent tens of thousands of lives saved annually.
How GLP-1 Drugs May Affect Addiction
The Brain Science: Why Weight-Loss Drugs Might Fight Cravings
The mechanism is still being investigated, but researchers have identified several plausible pathways:
Shared Reward Pathways
GLP-1 receptors are found in the ventral tegmental area (VTA) and nucleus accumbens — the same brain regions targeted by drugs of abuse. These areas drive the dopamine “reward” signal behind all addictions.
Quieting “Drug Noise”
Just as GLP-1 drugs quiet “food noise” (persistent preoccupation with eating), they appear to quiet the intrusive cravings that drive substance use. The desire doesn’t become aversive — it simply becomes uninteresting.
Cross-Substance Effects
Unlike existing medications that target specific substances (naltrexone for alcohol/opioids, buprenorphine for opioids), GLP-1 drugs may address a shared biological driver underlying ALL addictions — a common reward pathway dysregulation.
Animal Evidence
Vervet monkeys given semaglutide (the active ingredient in Ozempic) drank significantly less alcohol — not because it made them sick, but because alcohol had simply lost its appeal.[3]
What This Means — and What It Doesn’t
Putting the Research in Context
| What This Study Shows | What This Study Does NOT Show |
|---|---|
| Strong association between GLP-1 use and reduced addiction risk | That GLP-1 drugs directly cause addiction reduction (correlation ≠ causation) |
| Consistent effects across multiple substance types | That GLP-1 drugs are safe or effective as standalone addiction treatment |
| Significant harm reduction in people with existing addictions | How the drugs would perform in a general (non-diabetic) population |
| A plausible biological mechanism via shared reward pathways | Optimal dosing, duration, or which GLP-1 drug works best for addiction |
| Enough evidence to justify large-scale clinical trials | Enough evidence to prescribe GLP-1 drugs for addiction |
Important Limitations
- This is an observational study — it shows association, not causation
- The study population was primarily older, male VA patients with diabetes
- People who start GLP-1 drugs may be more health-motivated or receive more medical attention
- Long-term effects of GLP-1 use for addiction are unknown
- What happens when someone stops taking the medication is unclear
Clinical Trials Underway
The research community is moving rapidly. More than 15 clinical trials are in progress globally:[2]
Active Clinical Trials (2026)
- Brigham and Women’s Hospital / Harvard: Two trials for opioid use disorder and alcohol use disorder
- Penn State University: Multisite trial testing Ozempic for opioid use disorder
- NIDA (Baltimore): Evaluating semaglutide for alcohol reduction
- Novo Nordisk: Planned trial on alcohol consumption in liver disease patients
- Eli Lilly: Testing brenipatide for alcohol, tobacco, and opioid use disorders
- USC Institute for Addiction Science: Additional GLP-1 addiction trials
Well-designed alcohol use disorder trial results are expected within the next six months.
The Bigger Picture: What This Reveals About Addiction
Perhaps the most important insight isn’t about GLP-1 drugs at all — it’s about what these findings tell us about the nature of addiction itself.
The fact that a single medication class can reduce cravings across alcohol, opioids, cocaine, cannabis, and nicotine simultaneously suggests these seemingly different addictions share a common biological mechanism. As Dr. Al-Aly wrote in STAT, the desire for substances may all stem from the same biological source — and GLP-1 drugs may be the first medication to reveal that shared driver.[3]
Why This Matters Beyond the Medicine
Stigma remains the single greatest barrier to addiction treatment. An estimated 3% of people with alcohol use disorder ever receive effective medication. Research like this helps dismantle the myth that addiction is a moral failing by demonstrating its biological basis. Every study showing addiction operates through the same reward circuits as hunger and motivation brings us closer to treating it without shame.
Don’t Wait for Tomorrow — Effective Treatment Exists Today
While GLP-1 research offers hope for the future, highly effective, evidence-based addiction treatments are available right now. Waiting for a future breakthrough while addiction progresses is unnecessary and dangerous.
At Nova Transformations in Matthews, NC, we provide comprehensive addiction treatment:
Partial Hospitalization Program
7 hours/day, 5 days/week intensive treatment
Intensive Outpatient Program
Flexible 3 days/week while maintaining daily life
Dual Diagnosis Treatment
Addiction + co-occurring mental health conditions
Medication-Assisted Treatment
Sublocade, Vivitrol, naltrexone & more
We treat addiction to alcohol, opioids, cocaine, meth, fentanyl, heroin, benzodiazepines, and other substances through personalized, compassionate, evidence-based care.
Frequently Asked Questions
Not at this time. GLP-1 drugs like Ozempic are not FDA-approved for treating substance use disorders. They are currently approved only for type 2 diabetes and obesity. More than 15 clinical trials are in progress globally, with major results expected in 2026-2027. Until these trials conclude and potential FDA approval occurs, GLP-1 drugs should not be used off-label for addiction without medical supervision.
GLP-1 receptors exist in the same brain reward regions that drive addiction — the ventral tegmental area and nucleus accumbens. Ozempic appears to modulate these pathways, reducing cravings. Users describe it as quieting “drug noise” — similar to how the drugs quiet “food noise.” In animal studies, monkeys given semaglutide drank significantly less alcohol, not because it made them sick, but because alcohol simply lost its appeal.
Researchers analyzed health records from 600,000+ VA patients with diabetes over three years. Those on GLP-1 drugs had reduced risk of developing addiction: 25% lower for opioids, 20% for cocaine and nicotine, 18% for alcohol, and 14% for cannabis. Among patients already struggling with addiction, GLP-1 users experienced 50% fewer drug-related deaths, 39% fewer overdoses, 31% fewer ER visits, and 26% fewer hospitalizations. The protective effects appeared within the first year and persisted through the third.
Addiction has biological, psychological, social, and environmental components. This research powerfully highlights the biological dimension — the brain’s reward system — but effective treatment must address all dimensions. That’s why comprehensive programs combining medication with therapy (CBT, DBT, motivational interviewing), peer support, dual diagnosis care, and aftercare planning produce the best long-term outcomes.
Absolutely not. Never stop prescribed addiction medications without consulting your treatment provider. Existing FDA-approved medications — naltrexone, buprenorphine/Sublocade, methadone, acamprosate — have decades of rigorous clinical evidence supporting their safety and effectiveness. GLP-1 drugs are not yet proven or approved for addiction. Continue following your current treatment plan.
Multiple clinical trials are underway, with alcohol use disorder results expected in late 2026. However, FDA approval for a new indication typically requires years of additional review. A realistic timeline for potential approval is several years. In the meantime, highly effective, evidence-based addiction treatments are available today at facilities like Nova Transformations and should not be delayed.
The most effective approach combines evidence-based behavioral therapies (CBT, DBT, motivational interviewing), medication-assisted treatment when appropriate (naltrexone, Sublocade/Vivitrol, acamprosate), dual diagnosis care for co-occurring conditions like anxiety, depression, and PTSD, and comprehensive aftercare including support groups and relapse prevention planning. Programs like those at Nova Transformations integrate all of these components.
Don’t Wait — Effective Help Is Available Now
The GLP-1 research is exciting, but if you or a loved one is struggling with addiction today, proven treatment exists right now. Every day matters. Our compassionate clinical team is ready to help.
Related Articles
Alcohol Addiction Treatment
Comprehensive alcohol rehab in Charlotte, NC
Opioid Addiction Treatment
Evidence-based opioid recovery programs
Sublocade (MAT) in Charlotte
Medication-assisted treatment options
References
[1] Al-Aly Z, et al. “GLP-1 Receptor Agonists and Substance Use Disorders: A Target Trial Emulation Study.” The BMJ, March 4, 2026.
[2] Shen M, Suzuki J. “GLP-1 Receptor Agonists and Substance Use Disorders.” Harvard Gazette, February 2026. harvard.edu
[3] Al-Aly Z. “GLP-1 Drugs Appear to Silence ‘Drug Noise.'” STAT, March 4, 2026. statnews.com
[4] Young LJ. “Can GLP-1 drugs treat addiction?” Scientific American, March 4, 2026. scientificamerican.com
[5] Centers for Disease Control and Prevention. “Drug Overdose Deaths in the United States.” NCHS Data Brief, 2025.
[6] SAMHSA. “Key Substance Use and Mental Health Indicators: 2022 NSDUH.” 2023. samhsa.gov
All clinical content reviewed by the clinical team at Nova Transformations. Joint Commission accredited. Sources include The BMJ, Harvard Medical School, NIDA, SAMHSA, and Scientific American.
